Intravitreal Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment: A Systematic Review

被引：12

作者：

Balas, Michael ^{[1
]}

Abdelaal, Ahmed ^{[1
]}

Popovic, Marko M. ^{[2
]}

Kertes, Peter J. ^{[2
,3
]}

Muni, Rajeev H. ^{[2
,4
,5
]}

机构：

[1] Univ Toronto, Fac Med, Toronto, ON, Canada

[2] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada

[3] Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, Toronto, ON, Canada

[4] St Michaels Hosp, Dept Ophthalmol, Unity Hlth Toronto, Toronto, ON, Canada

[5] St Michaels Hosp, Dept Ophthalmol, Unity Hlth Toronto, 30 Bond St,Donnelly Wing,8th Floor, Toronto, ON M5B 1W8, Canada

来源：

OPHTHALMIC SURGERY LASERS & IMAGING RETINA | 2022年 / 53卷 / 10期

关键词：

INTRAOCULAR METHOTREXATE;

D O I：

10.3928/23258160-20220920-04

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

This systematic review evaluates the role of methotrexate (MTX) as an adjunctive intra-vitreal agent for the prevention and treatment of proliferative vitreoretinopathy (PVR) in rhegmatog-enous retinal detachment. Articles investigating the use of MTX in >= 5 patients with PVR or high risk of PVR were identified via searches of OVID MED-LINE, EMBASE, and Cochrane Library. Eight stud-ies and 240 eyes were included. Patients received an average 2.2 MTX injections with doses ranging from 250 to 400 mu g. After 10 months of follow-up in the three controlled trials, there was an 80% reti-nal re-attachment rate and 0.63 logMAR improve-ment in visual acuity for patients receiving MTX (n = 106), compared to an 83% reattachment rate and 0.30 logMAR improvement for controls (n = 91). Three mild complications related to MTX were reported. Further research is required given the low number of studies and quality of evidence, heterog-enous case selection and treatment regimens, high risk of bias, and lack of randomization.

引用

页码：561 / +

页数：13

共 40 条

[1] Clinical Variables Associated with Failure of Retinal Detachment Repair The European Vitreo-Retinal Society Retinal Detachment Study Report Number 4 [J].

Adelman, Ron A. ;

Parnes, Aaron J. ;

Michalewska, Zofia ;

Ducournau, Didier .

OPHTHALMOLOGY, 2014, 121 (09) :1715-1719

[2] Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy A Randomized Clinical Trial [J].

Ahmadieh, Hamid ;

Feghhi, Mostafa ;

Tabatabaei, Homa ;

Shoeibi, Nasser ;

Ramezani, Alireza ;

Mohebbi, Mohammad Reza .

OPHTHALMOLOGY, 2008, 115 (11) :1938-1943

[3]

Aldeyra Therapeutics Inc, The GUARD Trial-Part 1: A phase 3 clinical trial of repeated intravitreal injections of ADX- 2191 versus standard-of-care for prevention of proliferative vitreoretinopathy

[4] Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy [J].